SAN DIEGO, March 6, 2018
SAN DIEGO, March 6, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver corporate presentations at three upcoming investor conferences.
Details of these presentations are as follows:
- 30th Annual ROTH Conference
Time/Date: 3:00 p.m. PT on Tuesday, March 13, 2018
Location: Ritz-Carlton Laguna Niguel, Dana Point, CA
Room: Blue – Salon 2
- H.C. Wainwright & Co.'s 2nd Annual NASH Investor Conference
Time/Date: 10:40 p.m. ET on Monday, March 19, 2018
Location: St. Regis Hotel, New York
- Oppenheimer's 28th Annual Healthcare Conference
Time/Date: 2:10 p.m. ET on Tuesday, March 20, 2018 (webcast available)
Location: Westin New York Grand Central Hotel, New York
Room: Track 61
To access the live webcast of Viking's Oppenheimer conference presentation, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcast will be available on the Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. The company's clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist in Phase 2 development for hypercholesterolemia and non-alcoholic fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes. Viking is also developing novel and selective agonists of the thyroid beta receptor for GSD Ia and X-linked adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.
Follow Viking on Twitter @Viking_VKTX.
SOURCE Viking Therapeutics, Inc.